The company
Equillium, Inc.
EQ · Nasdaq
EQ stood above a rising 150-day average in 41 of the last 52 weekly readings, and has been out of that trend for the last 6 weeks. It is 43.1% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−9 points in four weeks); Health Care: 28% (−6 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 6
- Industry in uptrend
- 18% -9 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $5.3M
- Officials’ trades on record
- 0
- Institutions holding
- 60 (+11)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 41 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Stephen ConnellyPresident and CSO | sold | 30,975at $2.94 | 5 Jun 2026filed 5 Jun 2026 |
| Christine ZedelmayerSr. Vice President and COO | sold | 14,584at $2.93 | 5 Jun 2026filed 5 Jun 2026 |
| Stephen ConnellyPresident and CSO | sold | 200,000at $3.16 | 4 Jun 2026filed 5 Jun 2026 |
| Christine ZedelmayerSr. Vice President and COO | sold | 55,604at $2.70 | 28 May 2026filed 29 May 2026 |
| Christine ZedelmayerSr. Vice President and COO | sold | 200at $2.71 | 28 May 2026filed 29 May 2026 |
| Christine ZedelmayerSr. Vice President and COO | sold | 30,208at $2.98 | 28 May 2026filed 29 May 2026 |
| Penny TomPrincipal Accounting Officer | sold | 65,000at $2.95 | 28 May 2026filed 29 May 2026 |
| Christine ZedelmayerSr. Vice President and COO | sold | 9,821at $2.70 | 27 May 2026filed 29 May 2026 |
| Christine ZedelmayerSr. Vice President and COO | sold | 120,312at $2.50 | 13 Mar 2026filed 16 Mar 2026 |
| Christine ZedelmayerSr. Vice President and COO | sold | 181,219at $2.00 | 9 Mar 2026filed 11 Mar 2026 |
| Christine ZedelmayerSr. Vice President and COO | sold | 109,375at $1.78 | 19 Feb 2026filed 23 Feb 2026 |
| Christine ZedelmayerSr. Vice President and COO | sold | 76,562at $1.74 | 19 Feb 2026filed 23 Feb 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| Jupiter Topco LLCnew · filed 14 Aug 2026 | 6,494,571$20.7M | +6,494,571 |
| Decheng Capital LLCunchanged · filed 14 Aug 2026 | 4,447,308$14.2M | 00.0% |
| Affinity Asset Advisors, LLCadded · filed 13 Aug 2026 | 4,100,000$13.1M | +2,873,690+234.3% |
| ADAR1 Capital Management, LLCadded · filed 14 Aug 2026 | 3,758,569$12.0M | +31,910+0.9% |
| Aberdeen Group plcadded · filed 31 Jul 2026 | 3,631,659$11.6M | +278,822+8.3% |
| Woodline Partners LPunchanged · filed 14 Aug 2026 | 3,500,901$11.2M | 00.0% |
| RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 2026 | 3,096,336$9.9M | 00.0% |
| STEMPOINT CAPITAL LPnew · filed 14 Aug 2026 | 2,016,607$6.5M | +2,016,607 |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 1,822,812$5.8M | +38,340+2.1% |
| Eversept Partners, LPadded · filed 14 Aug 2026 | 1,520,824$4.9M | +21,831+1.5% |
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.